Product Defect Alert
HPS Pharmacies wish to advise that Phebra, in consultation with the Therapeutic Goods Administration (TGA), has given notice of a product defect alert for Ospolot® as follows:
Sulthiame 200 mg
This product defect alert has been initiated as affected batches have been supplied with child-resistant caps that may not function correctly. This carries a potentially life-threatening risk of poisoning if a child was able to access and accidentally ingest this medicine.
The batches affected by this issue are:
- 18003717 (expiry May 2021)
- 28811 (expiry November 2022)
The TGA advises that consumers take extra caution when storing medicine from the affected batches.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Phebra on (02) 9420 9199, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates